Chia Tai Tianqing Pharmaceutical discovers new WRN inhibitors
Dec. 1, 2025
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of colorectal cancer.